Adults 12 to 18, any sex, with Post-traumatic Stress Disorder or Alcohol Abuse. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Patients With High Levels of Adolescent PTSD SymptomsPrimary· Baseline (injury), then 2, 5, and 12 months post-injury
Patients with symptoms consistent with a diagnosis of PTSD on the UCLA PTSD Reaction Index were counted. The UCLA PTSD-RI can be used to create an algorithm consistent with a diagnosis of PTSD by rating 1 intrusive, 3 avoidant, and 2 arousal symptoms with a rating of moderate severity. The PTSD-RI is scored on a scale from 0 (none of the time) - 4 (most of the time) with a \> = 2 "some of the time" denoting this cutoff for moderate severity. This algorithm was used to identify patients with high PTSD symptom levels consistent with a diagnosis of PTSD.
Baseline
Group
Value
95% CI
Intervention
9
Control
12
2-months
Group
Value
95% CI
Intervention
11
Control
12
5-months
Group
Value
95% CI
Intervention
9
Control
13
12-months
Group
Value
95% CI
Intervention
12
Control
9
Number of Patients Who Self-reported Alcohol Consumption or Drug UseSecondary· Baseline (injury), and 2, 5, and 12 months post-injury
Any self-reported alcohol or drug use using one yes or no question
Baseline
Group
Value
95% CI
Intervention
28
Control
25
2-months
Group
Value
95% CI
Intervention
18
Control
14
5-months
Group
Value
95% CI
Intervention
19
Control
21
12-months
Group
Value
95% CI
Intervention
22
Control
26
Percentage of Asolescents Linked to Primary Care During the StudySecondary· Up to12 months post-injury
Percentage of adolescents self-reporting one or more primary care visits over the course of the 12-months after the injury
Group
Value
95% CI
Intervention
43
Control
48
Percentage of Adolescents Who Self-reported Weapon CarriageSecondary· Baseline (injury), then 2, 5, and 12 months post-injury
Self-reported carrying of knife, gun, club or other weapon by adolescent
Baseline
Group
Value
95% CI
Intervention
20
Control
19
2-months
Group
Value
95% CI
Intervention
8
Control
15
5-months
Group
Value
95% CI
Intervention
5
Control
13
12-months
Group
Value
95% CI
Intervention
4
Control
13
Number of Patients Experiencing High-Level Depressive SymptomsSecondary· Baseline (injury), then 2, 5, and 12 months post-injury
The investigators used the Patient Health Questionnaire (PHQ-9) to identify symptoms consistent with a diagnosis of depression on the 9-item Patient Health Questionnaire depression screen. Scores range from 1 to 27 with higher scores representing worse outcomes.
Baseline
Group
Value
95% CI
Intervention
4
Control
8
2-months
Group
Value
95% CI
Intervention
3
Control
4
5-months
Group
Value
95% CI
Intervention
2
Control
4
12-months
Group
Value
95% CI
Intervention
7
Control
6
Adverse events — posted to ClinicalTrials.gov
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Recent needs assessments suggest that difficulties exist in care coordination between emergency medical services (EMS) systems and primary care for injured adolescents with alcohol problems and post-traumatic stress disorder (PTSD). This project will implement, evaluate, and disseminate the adolescent trauma support service model program that aims to enhance coordination between EMS systems and primary care/community services.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07430852 — Inherited and Environmental Risks Acting on Body Weight
· NA
· not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc
· Phase 2
· not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn
· NA
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 19 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00619255.